Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;42(6):e3312.
doi: 10.1002/hon.3312.

Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)

Affiliations

Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)

Maria Cristina Pirosa et al. Hematol Oncol. 2024 Nov.

Abstract

Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (n = 24). The most common histological subtype was diffuse large B-cell lymphoma (DLBCL, n = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first-line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow-up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5-year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause-specific, and progression-free survival in patients with DLBCL.

Keywords: CNS prophylaxis; chemotherapy; female reproductive system; lymphoma.

PubMed Disclaimer

Conflict of interest statement

MCP: travel grant Beigene, Janssen; EZ: Research Funding (Institutional): AstraZeneca, Beigene, Celgene/BMS, Incyte, Janssen, Roche; Honoraria (Medical educational event): Abbvie; Honoraria (Advisory Board): AbbVie, BeiGene, BMS, Curis, Eli/Lilly, Incyte, Ipsen, Merck, Miltenyi Biomedicine, Roche; Travel grants: AstraZeneca, BeiGene, Janssen, and Gilead; AS: Institutional funding for clinical trials: Abbvie; ADC Therapeutics; Amgen, Astra Zeneca; Bayer; BMS; Cellestia; Incyte, Loxo Oncology; Merck MSD; Novartis; Pfizer; Philogen; Prelude Therapeutics; Roche; Consultant/expert testimony/advisory board (institutional): Debiopharm, Janssen, AstraZeneca, Incyte, Eli Lilly, Novartis, Roche, Loxo Oncology; Travel grant: Incyte; Astra Zeneca; all the other coauthors have not COI.

References

    1. Harris NL, Scully RE. Malignant lymphoma and granulocytic sarcoma of the uterus and vagina. A clinicopathologic analysis of 27 cases. Cancer. 1984;53(11):2530‐2545. 10.1002/1097-0142(19840601)53:11<2530::aid-cncr2820531127>3.0.co;2-j - DOI - PubMed
    1. Lagoo AS, Robboy SJ. Lymphoma of the female genital tract: current status. Int J Gynecol Pathol. 2006;25(1):1‐21. 10.1097/01.pgp.0000183049.30212.f9 - DOI - PubMed
    1. Woodruff JD, Noli C, Novak ER. Lymphoma of the ovary. A study of 35 cases from the ovarian tumor registry of the American gynecological society. Am J Obstet Gynecol. 1963;85:912‐918. - PubMed
    1. Kaplan EJ. Commenting on “HIV‐associated primary cervical non‐Hodgkin's lymphoma and two other cases of primary pelvic non‐Hodgkin's lymphoma” by Pham et al. 90:204‐6. Gynecol Oncol. 2004;93(3):719‐720. author reply 20. - PubMed
    1. Heredia F, Bravo M, Pierotic M, Majlis A, Carmona L. Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non‐Hodgkin's lymphoma of the uterine cervix. Gynecol Oncol. 2005;97(1):285‐287. 10.1016/j.ygyno.2004.12.018 - DOI - PubMed

LinkOut - more resources